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ABSTRACT 
 Levetiracetam (LEV) is an antiepileptic drug (AED) that has been shown to 
mainly enhance synaptic depression and modulate certain voltage and ligand-gated 
channels, after it gains entry into neurons through endocytosis. Since synaptic terminals 
and distal axons are the first compartments exposed to LEV, we utilized a crayfish motor 
axon preparation to investigate whether LEV modulates axonal excitability. Two 
electrode current clamp from the inhibitor axon of the crayfish opener showed that LEV 
reduced action potential amplitude (APamp) and enhanced synaptic depression, although 
these events did not occur at the same time, the latter occurred later than the reduction in 
APamp. Further examinations of these effects and comparison of antidromic and 
orthodromic conducting action potentials in LEV suggests that this drug preferentially 
reduces excitability of the proximal axon despite the expectation that it enters the axon at 
terminals and reaches distal branches first. Results presented here demonstrate that LEV 
modulates axonal excitability, which may also contribute to its antiepileptic effects. 
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INTRODUCTION 	
Introduction to Epilepsy 
                 Epilepsy is a chronic neurological disorder, usually characterized by 
unpredictable, unprovoked recurrent seizures that affect a variety of mental and 
neurological functions. Seizures result from a shift in the normal balance of excitation and 
inhibition within the CNS. According the the epilepsy foundation, epilepsy is one of the 
most common neurological diseases, affecting more than 3 million people in the U.S. and 
about 50 million people worldwide. Given seizure’s unpredictable onset and incapacitating 
nature, it is clear how they can greatly diminish the independence and serenity of 
individuals that experience them. In cases where seizures are severe enough, they can result 
in permanent brain damage.  
 
            There are many kinds of seizures, each with characteristic symptoms and 
electrophysiological disturbances that can usually be detected in scalp 
electroencephalographic (EEG) recordings (Ahmmad et al. 2014).  The most recent 
classification system is based on the location where seizure originates in the brain, the level 
of awareness during the seizure and whether movements occur during the seizure (Epilepsy 
Foundation. 2019). According to this classification system there are three main types of 
seizures: focal, generalized and unclassified. Focal seizures are mainly confined to discrete 
areas within the cerebral cortex, whereas generalized seizures arise from both cerebral 
hemispheres and diffuse across different regions of the brain. Unclassified seizures refer to 
seizures with an unknown time of onset and an undefined location for where the seizure 
		 2 
started in the brain.  For example, seizures that occur when the patient is asleep are termed 
unclassified until further information is acquired in order to be diagnosed as generalized or 
focal. It is worth mentioning that the seizure classification system is based strictly on the 
clinical features and not the etiology nor the cellular substrate associated with the seizure 
(Goldenberg. 2010).  
Review on First Generation Antiepileptic Drugs: 
                 The treatment options for epilepsy have come a long way from the bromides to 
the current era in which we now have multiple treatment modalities, including 
medications, implantable devices, and surgery. However, antiepileptic drugs remain as 
the central treatment for epilepsy with 70% of children achieving good control with 
medications alone (Sankaraneni et al. 2015). Although the progress in drug development 
and the increasing choices of medication targets, AEDs are still lacking the ability to 
reverse or stop the underlying mechanism of epileptogenesis (Hanaya & Arita. 2016). 
Therefore, it is not surprising that, despite the wide array of AED choices, the prevalence 
of drug-resistant epilepsy has not been reduced and about a one-third of epilepsy patients 
remain in intolerable conditions (Harjeet at al 2016). Achieving a comprehensive 
understanding of how AEDs counter epilepsy on a cellular level advances us towards 
realizing the full potential of those drugs that are currently on the market as well as in 
predicting the efficacies of new AEDs (Meehan et al. 2011). 
                        Since recurrent seizures are a manifestation of excessive hyper-excitability 
of neuronal networks, the development of the first generation of antiepileptic drugs mainly 
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operated upon this logic. The first generation AEDs focused on stabilizing neuronal 
function, reducing neuronal synchronization and reducing neurotransmitter and 
neuropeptide release (Cook & Bensalem-Owen. 2011). Consequently, all the classical 
AEDs dampen neuronal excitability.  The cellular mechanism of these effects on neuronal 
networks can be categorized into three main groups: facilitation of inhibitory transmission 
by potentiating GABA function, blockade of voltage-gated Na+ and/or Ca++ channels and 
attenuation of excitatory transmission (Davies et al 1995; Kwan & Brodie. 2000; Kwan et 
al. 2001).  The most common first generation AEDs such as phenytoin, carbamazepine and 
valproate exert their action by partially blocking fast inactivating sodium channels (Cook 
& Bensalem-Owen, 2011). However, most AEDs exhibit more than one cellular 
mechanism of action or target more than one type of channel. As a result, it is often unclear 
which mechanism is responsible for the given antiepileptic effects of the drug (Söderpalm 
B et al. 2002). For example, Valproic Acid, an AED with the broadest profile of clinical 
uses, is known to block voltage gated sodium channels and potentiate GABA responses at 
high concentrations while also reducing T-type calcium currents (Loscher 1998; Rogawski 
1990). As a consequence of the broad profile of most AEDs, the less defined cellular 
mechanism of action and the complex nature of epilepsy pathology, resolving an optimal 
treatment for drug resistant patients remains a challenge (Nobels J. 2015).  
 
               Historically the defects in epilepsy genes gave critical insights to the pathological 
mechanisms of seizures. In particular, the set of molecular targets used to develop 
traditional AEDs overlaps with 'epilepsy genes' that have been identified. These genetic 
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associations have aided seizure management in epileptic patients. One example is the 
SCN1A gene that codes for the α-subunit of the neuronal sodium voltage-gated channel. 
Mutations with the SCN1A gene are known to cause a variety of epilepsy conditions such 
as febrile seizures and Dravet syndrome in children (Marini et al. 2009; Escayg and Goldin 
2010). These mutations were later shown to be the molecular target for many AEDs such 
as phenytoin, carbamazepine, and lamotrigine (Abe et al 2008). Furthermore, it was 
suggested that the genetic variations among patients influenced their responsiveness to 
certain medications. For instance, PCR analysis of 130 patients of whom 50 were drug 
resistant showed that there was a significantly higher AG genotype and a higher G allele 
of the SCN1A polymorphism in drug resistant patients (El Fatoh et al. 2016). Additionally, 
it was illustrated that patients with AA genotype polymorphism of the SCN1A gene 
required higher doses of phenytoin and carbamazepine for seizure control than those 
patients who had the GG genotype (Hirose S. et al 2013). Taken together, these results 
suggest that genetic targets could be a valuable tool in predicting the efficacy of specific 
drug treatment. It should be noted, however, that the action of AEDs on brain targets is 
often to counter the functional defect in a genetic epilepsy syndrome. Therefore, all 
classical AEDs are mainly controlling the symptomology of epilepsy and not in any way 
reversing or preventing seizures (Ragawski & Loscher, 2004). As a result of these 
limitations, classical AEDs are only a step on the way to the ultimate goal of epilepsy 
medicine, which is to provide treatments that prevent epilepsy or reverse it. 
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The Discovery of the Antiepileptic Drug LEV 
         Levetiracetam (LEV) was discovered by a random screening using a sound-induced 
seizure model. The drug showed protective activity against all phases of seizure activity. 
Interestingly, it was later illustrated that LEV has no anticonvulsant activity in the two 
classical screening models for AEDs: the maximal electroshock seizure (MES) and the 
pentylenetetrazol seizure tests (PTZ) (Loscher and Honack 1993; Klitgaard et al. 1998). 
However, LEV was effective in treating most chronic models of epilepsy. For instance, 
LEV prevented audiogenic seizures in mice and protected against the effects of 
chemoconvulsants (Gower et al. 1995). Also, LEV was able to exert anticonvulsant 
activity against both focal and secondarily generalized seizures in the amygdala-kindled 
rat model (Loscher and Honack 1993; Loscher et al. 1998). When fully kindled rats were 
pretreated with LEV hours before stimulation, the resultant seizure episode was lesser in 
severity and shorter in duration. Moreover, LEV has shown protective effects against 
spontaneous spike and wave discharges in the GAERS (genetically induced) seizure 
models and in pilocarpine and kainic acid (chemically induced) seizure models in rats. In 
addition to its antiepileptic effects, LEV has the most efficacy among the GABAergic 
medications in these epilepsy models and a higher safety margin (Gower et al. 1995). 
Consequently, the outcomes of the clinical studies with LEV supporting the drug’s 
efficacy in treating seizures and the lack of persisting side effects has led to its approval 
by the Food and Drug Administration in 1999. 
		 6 
                 Levetiracetam has several advantages over other AEDs. Relative to first 
generation AEDs, LEV exhibits lower toxicity and is more tolerable to epileptic patients. 
Equally, LEV exhibits less drug interactions and is ideal for broader epilepsy treatment 
(Cook & Bensalem-Owen. 2011; Hovinga 2001). The most notable drug interaction is the 
strong inducing of cytochrome P450 and glucuronizing enzymes (as well as P-
glycoprotein) by AEDs such as Carbamazepine, phenytoin, phenobarbital and primidone. 
This interaction can cause a reduction in the efficacy of co-administered medications such 
as oral anticoagulants, calcium antagonists, steroids, antimicrobial and antineoplastic 
drugs. Drug-drug interactions can have beneficial effects, such as the therapeutic synergism 
of valproic acid combined with lamotrigine. However, adverse effects such as the 
reciprocal potentiation of neurotoxicity observed in patients treated with a combination of 
sodium channel blocking antiepileptic drugs can complicate poly-therapy approaches 
specially in drug resistant patients (Johannessen and Landmark 2010; Zaccara and 
Percucca 2007). Remarkably, Levetiracetam have not been reported to cause or be a target 
for clinically relevant drug interactions (Perucca E. 2006). However, despite LEV’s 
efficacy and preference among physicians as an add-on medication for epilepsy the exact 
mechanism of LEV remains not fully understood.  
              LEV is considered to be among the new generation of therapies due to its unique 
pharmacological profile. The highly selective action in "epileptic" animals distinguishes 
Levetiracetam from traditional and other new AEDs (Klitgaard et al. 1998). For instance, 
sodium channel blockers dampen overall excitation and their clinical application ranges 
from treating seizures and managing neuropathic pain (Kalso E. 2005), in contrast to the 
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traditional AEDs which act mainly on increasing overall inhibition by potentiating GABA. 
LEV selectivity inhibits seizure like hyper-excitability in neurons and does not affect 
normal neuronal activity (Meehan et al 2011). Moreover, LEV seems to have a specific 
action that is strongly linked to the mechanisms of seizure development. Administration of 
LEV in a kindling model of temporal lobe epilepsy prevented and curtailed the acquisition 
of amygdala-kindling in rats. Additionally, after the termination of LEV administration, 
the duration of seizures recorded from the amygdala remained shorter. These results 
suggest that LEV does not simply mask the symptoms of seizure though an anticonvulsant 
action, but it exerts distinct antiepileptogenic effect (Loscher et al 1998). These findings 
support the notion that LEV can protect against the neurobiological changes that contribute 
to the development of seizers. As a consequence of its unique activity, LEV became a target 
for further development of novel pharmacological agents that can not only suppress 
seizures but also potentially prevent or reverse the process of epileptogenesis (Margineanu 
and Klitgaard. 2003). 
 
The Unique Mechanism of Levetiracetam: 
             LEV possesses several properties that distinguish it from the classical AEDs. The 
chemical profile of LEV suggests that it is unlikely that this compound exerts its’ effects 
through the classic mechanistic categories of AEDs. Previous studies have concluded that 
LEV does not involve the modulation of voltage-gated ion channels nor the binding to 
receptors associated with excitatory or inhibitory neurotransmitters. Electrophysiological 
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studies showed that LEV did not modulate voltage-gated sodium channels in cultured 
pyramidal neurons in CA1 slices nor did it regulate the activity of voltage-gated potassium 
currents in cultured hippocampal neurons (Zona et al. 2001; Bischoff and Schlobhm 2002).  
Other studies have also supported this hypothesis by showing that LEV did not modulate 
low voltage gated calcium channels know as T-type Ca2+ currents (Zona et al. 2001).	
Equally, LEV had no effect on G-protein coupled receptors in second messenger pathways 
such as cyclic adenosine monophosphates and protein kinase C (Shorvon et al. 2002; 
Lukyanetz et al. 2002). Because LEV did not fit any of the previously described 
mechanisms of AED, therefore, it was hypothesized that LEV operated in a unique 
undefined mechanism.  
             The fact that LEV showed no activity in normal electrophysiological conditions 
deviated the research approaches from the molecular targets of traditional AEDs. 
Encouraged future research to look beyond the traditional molecular targets of AEDs.  A 
group led by Lukyanetz hypothesized that LEV might be modulating high voltage 
activated (HVA) Ca+ currents. The use of Pharmacological blockers allowed the group to 
separate the different Calcium currents modulated by LEV.  The results demonstrated 
that at its highest concentrations LEV did not influence the activity of L-, P- or Q-type 
Calcium channels in CA1 neurons, while it selectively and partially inhibited the activity 
of N-type calcium channels. Furthermore, the results of the study indicated that the action 
of LEV did not alter the steady-state inactivation of Calcium channels (Lukyanetz et al. 
2002). The selectivity of LEV’s action on HVA currents explains its potency in 
modulating hyper-excitatory activity during seizures. Farther, N-type Calcium channels 
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are located in presynaptic terminals and they are well known for their role in modulating 
neurotransmitter release and secretary vesicle fusion processes (Chin. 1998). More 
specifically, N-type channels bind to syntaxin, one of the t-SNAREs present on the 
presynaptic membranes, thereby placing the VGCC in molecular proximity to the 
proposed SNARE complexes which included SNAP-25 and synaptotagmin (Bennett et 
al., 1992; Leveque, et al., 1994).  These known roles of N-type channels and LEV’s 
specificity in modulating their activity further facilitated future approaches in examining 
a possible presynaptic mechanism for LEV’s action. 
               The hypothesis that LEV might exert its’ antiepileptic activity via binding of 
vesicle proteins was based on the logic of SV2 synaptic protein isoforms being involved in 
regulating presynaptic calcium levels in seizure models. A study demonstrated that SV2A- 
and SV2B double knockout mice were experiencing severe seizures and were not able to 
survive. The results of the study revealed that neurons lacking the SV2 proteins 
experienced accumulation of Ca2+ during acute action potentials which in turn caused 
abnormal neurotransmitter release that destabilized synaptic circuits and induced to 
epilepsy (Janz et al. 1999). Molecular data supported this logic by examining of LEV’s 
binding distribution across the brain using immunochemistry which illustrated great 
overlap with SV2A protein distribution (Bajjalieh et al 1994; Gillard et al. 2005). The 
major pivotal point in LEV’s history, however, was when the article by Lynch and his 
group successfully highlighted a strong correlation between the binding affinity of LEV 
and SV2A expression in fibroblasts. Using titrated LEV and autoradiography, the group 
put forward a novel mechanistic link between the vesicle protein SV2A and LEV’s 
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antiepileptic properties. These findings were further validated when another study provided 
a clear correlation between LEV’s efficacy with the presence of SV2A using SV2A 
heterogeneous knockout mice that showed resistance to LEV’s antiepileptic effects 
(Kaminski et al. 2004). As a result, LEV was then hypothesized to have a completely 
unique vesicular mechanism that distinguishes it from classical AEDs.   
             These studies set the bases for the neurophysiological properties of LEV and the 
possibility of a presynaptic vesicular mechanism for this drug. The presynaptic effects of 
LEV were first put forward when it was noted that a three-hour long exposure to LEV was 
required to show a remarkable altered response in hippocampal CA1 slices during a paired-
pulse stimulation protocol. Additional imaging data further validated this presynaptic 
hypothesis by demonstrating that LEV reduced the rate of vesicle release, using a FM1-43 
distaining protocol, during high frequency stimulation (Yang et al. 2007). These results 
suggested that chronic exposure to LEV significantly reduced synaptic transmission during 
high frequency stimulation.  A later study conducted by the same group was able to 
establish a time-frame for the delay onset of LEV’s effects on synaptic transmission.  This 
latency was shown by delivering repetitive stimulation over the period of three hours. It 
was speculated that a three-hour period was needed to detect the effects of LEV because 
LEV’s entry into neurons requires binding to SV2A which is only accessible to LEV during 
vesicle recycling (Yang & Rothman. 2009). These findings support a presynaptic 
mechanism for LEV’s antiepileptic properties with the possibility of modulating synaptic 
transmission.  
		 11 
              Following the discovery of an interaction between LEV and SV2A, the research 
deviated towards highlighting the consequence of this interaction on seizure activity in 
neuronal networks. A study by Boido and colleagues was one of the few to examine the 
genetic basis of LEV’s effects on specific molecular targets. The group used Synapsins 
(SynI, SynII, SynIII) as their genetic target to resolve the presynaptic mechanism of LEV 
on the epileptic phenotype in these mouse models (Boido et al. 2010). Synaptsins I, II and 
III are known to be major synaptic vesicle (SV) proteins.  They control SV trafficking 
between the reserve pool and the readily-releasable pool (Chi et al. 2001). Synapsins also 
play an integral role in modulating overall synaptic strength and plasticity. It was 
previously shown that deletion of the SYN1 gene caused an increase in excitatory PSCs 
while reducing inhibitory PSCs in hippocampal SYN1 KO neurons. The alterations in the 
excitatory to inhibitory ratio causes neuronal networks to be hyper-excitable and exhibit 
high burst synchronization which eventually induced seizures in the SYN1 KO mouse 
models (Chiappalone et al 2009). Interestingly, data from Patch-clamp recordings in CA1 
neurons in another study suggested that LEV would counter the excess in excitability in 
the mutants by increasing the inhibitory to excitatory ratio. Intracellular recording analysis 
revealed mainly biphasic excitatory inhibitory potential shifts due to LEV. The overall 
action of LEV was increasing the inhibitory-excitatory ratio alongside potentiating 
inhibition. These findings suggest that LEV functions by lowering the overall excitation 
threshold of the network and making it less excitable.  Additionally, results from 
immunoblotting experiments confirmed that a decrease of LEV efficacy was accompanied 
by a decrease in SV2A expression in the triple knockout slices confirming SV2A’s role in 
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mediating the action of LEV (Boido et al. 2010). However, despite the progress made in 
resolving the physiological consequence of this interaction the literature lacked any clear 
molecular mechanism for the physiological effects of the drug.  
                A follow-up study was able to identify LEV’s location of entry into the SV2A 
protein binding site. The study aimed to resolve the timeframe of LEV’s effects on the 
presynaptic terminals by manipulating the kinetics of vesicular recycling.   In order to do 
so, the researchers applied electrical stimulation on hippocampal slices in a hypertonic 
sucrose to load LEV onto the slices. By using FM1-43 (membrane selective dye) and 
fluorescence to visualize the active terminals the group was able to visually quantify the 
time needed for LEV to bind to SV2A and the timeframe to be unloaded from the slices. 
The results from the study supported the hypothesis that LEV enters vesicles during vesicle 
recycling and acts by binding to an intra-vesicular binding site. The most interesting 
observation was that LEV reduced transmission through depleting the readily releasable 
pool (RRP) without effecting the rate of replenishment. Additionally, the group was able 
to demonstrate and explain LEV’s selectivity for high frequency firing by showing a 
dissociation in LEV’s antiepileptic effects between delivery in low and high frequency 
stimulations. Specifically, LEV did not have a notable effect on EPSP activity during low 
frequency stimulation in contrast while synaptic transmission during high frequency 
stimulation was reduced. The results also confirmed that LEV reduced the RRP while 
keeping the rate of replenishment unaffected (Meehan at al. 2011). Collectively, these 
results confirm LEV’s interaction with SV2A by binding to its target during vesicle 
recycling and influencing excitability via inhibiting transmission. However, since SV2A’s 
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role in synaptic transmission and vesicle tracking is not well established, the exact 
mechanism in which LEV’s interaction with SV2A reveres epileptic activity remains a 
mystery.  
The purpose of this Study 
           Literature review for both molecular and physiological studies, provide analysis that 
show LEV primarily modulating molecular synaptic transmission. However, several 
studies suggest that voltage gated channels could also be modulated by LEV. If LEV can 
act on voltage gated channels, axonal branches and synaptic terminals. Then synaptic 
terminals should be the first neuronal compartment exposed to the effects of LEV. The goal 
of this study is to investigate possible effects of LEV on the overall excitability of the axon. 
We utilized a crayfish opener preparation to examine LEV’s effects.  The NMJ preparation 
allows us to preform two-electrode current clamp (TECC) from motor axons, patch clamp 
on presynaptic terminals and record synaptic potentials from muscle fibers (Lin 2016; 
2013; 2012). Thus this preparation allows us to examine the possible effects of LEV on 
synapses and the axons. We can address questions regarding both pre- and post-synaptic 
mechanisms. The long term stability of the recordings and the ease of access to the axons 
for electrophysiology makes this preparation ideal for examining the delay onset of LEV’s 
action. In this report, we describe the effect of LEV on the inhibitory axon as well as its 
effects on synaptic transmission.  
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Methods 
 
Dissection and preparation. 
 
 Crayfish, Procambarus clarkii, with a head-to-tail length of ~5-7 cm, were used in all 
experiments. Animals of both sexes were immobilized on ice and decapitated by cutting 
behind the eye stocks. The opener neuromuscular junction dissection and recording have 
been detailed before (Lin 2012). The opener of the first walking leg was taken from 
animals that were later used for VSF experiments. All dissections and recordings were 
performed at room temperature. 
 
Crayfish saline contained (in mM): 195 NaCl, 5.4 KCl, 13.5 CaCl2, 2.6 MgCl2, and 10 
HEPES (pH=7.4). The saline was circulated by a peristaltic pump at a rate of 1 
ml/minute. LEV (Sigma-Aldrich L8668) was dissolved in distilled water (100 mM) and 
stored in -20°C until use. Unless otherwise indicated, LEV concentration of 100 µM was 
used, which is considered the effective therapeutic concentration (Loscher et al. 2016). In 
order to maximize transmitter release and LEV entry through vesicular recycling, 200 
µM 4-AP was added to the saline in the preparations unless indicated otherwise.  
 
Electrophysiology 
 
Intracellular electrodes for inhibitory axon were filled with 0.5 M Kmethansulphonate 
(40-60 MΩ). Electrodes for muscle fiber recording were filled with 3M KCl (~10 MΩ). 
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Stable resting membrane potential (Vm) could be maintained, in axons and muscle fibers, 
for 4-6 hours. Input resistance (Rin) of axon increased over this period, presumably due to 
the methansulfonate salt used in the electrode (Kaczorowski et al. 2007). The axons were 
stimulated by a series of one second long current steps, from subthreshold to 
suprathreshold. In order to ensure LEV uptake, the largest current step in each 
experiment typically fired APs at 50~70Hz. This protocol could only be applied to the 
inhibitory axon, excitatory axon thus activated invariably triggered strong muscle 
contraction. All recordings were filtered at 2 KHz and sampled at 40 KHz. The data were 
collected as two-second long traces at a rate of 0.1 Hz. Data acquisition (National 
Instrument) and analysis used IGOR (Lake Oswego, OR). 
 
 
Results 
 
Inhibitory motor axon stimulation was achieved with TECC. When the current 
injection electrode is near the primary branching point of the axon, current steps in the 
range of 6 to 7 nA were required to initiate AP firing. (See Fig.3A1 rectangular inset for 
orientation). The Firing frequency increased with larger current injection. Figure 1A 
illustrates APs firing at ~40Hz (A2), activated by current step of 11 nA, and IPSP 
simultaneously recorded with a third electrode in a muscle fiber (A1). There was a clear 
reduction in AP and IPSP amplitudes after LEV delivery (grey traces). The top panel of 
Figure 1B show that the firing frequency (right vertical scale) activated by the same 
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current step as that used in A2 remained stable over a period of eighty minutes. The 
lower panel displays changes in APamp, activated by the current step over the same 
period. Every APamp evoked by the current step was measured and displayed on the Y-
axis, while the X-axes registers the trace number and time at which the recording was 
obtained (Fig.1C). APamp remained stable after LEV was introduced until an abrupt 
decrease occurred 15 minutes later. (The “*” identify the time points where traces were 
selected for display in A1 and A2.) Aligning the first AP recorded before and after LEV 
in A2 shows that the reduction in APamp was accompanied by an increase in AP half-
width and a slight depolarization of the after-potential (Fig.1D). Rin, monitored by a 
hyperpolarizing current pulse (Fig.1A2 arrow), remained stable. The delay between LEV 
delivery and APamp reduction varied from 6 to 20 minutes (n=5). In five preparations, the 
average APamp in LEV, measured 30 minutes after the APamp down turn occurred, was 
significantly reduced (81±4% of control value, p=0.009, paired Student’s t-test). 
 
In two additional preparations, LEV was tested in the absence of 4-AP. There was 
no reduction in APamp in one preparation, monitored for 100 minutes after LEV 
introduction, and a 10% reduction was detected in the second preparation 70 minutes 
later, which is notably longer than those observed in 4-AP. 
 
IPSP activated by every AP in each trace was measured and displayed in the same 
format as that of the corresponding APamp (Fig.1C). Data point scattering along Y-axis 
reflects the strong facilitation of this synapse. A reduction in IPSP occurred 30 minutes 
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after LEV perfusion started. The delay is distinctively longer than that of reduction in 
APamp. Since the firing frequency evoked by the same current step did not change 
significantly during the course of this experiment (Fig.1B upper panel), the reduction and 
compression of IPSP amplitude in LEV was unlikely to be due to a reduction of AP firing 
frequency and a weakened facilitation. Instead, the compression most likely corresponds 
to an enhanced synaptic depression previously reported in mammalian CNS synapses 
(Yang et al. 2007).  
 
The decline in IPSP amplitude occurred later than that of APamp, by 15 minutes in 
Fg.1C. The decline in IPSP in LEV was observed in four out of four preparations and its 
timing consistently lagged behind that of APamp, 30-55 minutes after LEV application. 
(IPSP amplitude reduction was not quantified. Small driving force for Cl- in combination 
with low release probability makes the first and unfacilitated IPSP difficult to resolve. 
The number of APs fired by the same current steps tent to increase during a long 
experiment (Fig.2), which makes comparison of facilitated IPSP difficult.  
 
In one of the two preparations where 4-AP was omitted in saline, IPSP reduction 
in LEV occurred in the preparation where APamp also decreased with an after-LEV delay 
of 90 minutes. In the second preparation, neither APamp nor IPSP was affected by LEV 
after ninety minutes.  
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We next examined whether the LEV effects were reversible in the opener 
preparation. Figure 2 illustrates an attempt to washout LEV effects. The abrupt downturn 
in APamp and IPSP after LEV were similar to that shown in Figure 1. There was a 
continuous increase in Rin in this preparation, which resulted in increase in the number of 
APs and the density of IPSP data points evoked by the same current step. Nevertheless, 
the reduction in IPSP is clear and also exhibits a delay distinctly later than that of APamp. 
Washing the preparation with control saline plus 200 µM 4-AP could not reverse the 
inhibition. The washout was tested in four preparations, with washing duration ranging 
from 20 to 120 minutes, and none showed any sign of recovery. The efficiency of the 
perfusion system is indicated by the near-instantaneous increase in APamp and IPSP after 
4-AP was added near the beginning of the time line (grey arrowhead in Fig.2A). Thus, we 
conclude that LEV’s effect is not reversible within the time frame of our preparation. 
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Figure 1. LEV reduced AP amplitude and IPSPs at the opener preparation. IPSP (A1) and        AP (A2) 
recorded before and after 100 µM LEV. The AP train was induced by an 11 nA and 1 second current step. A 20nA-20ms 
hyperpolarizing step (A2 arrow) was used to monitor Rin. APamp was measured from AP threshold, defined as when dv/dt=25V/s, to 
peak. (B) Upper panel: APfreq calculated during the current step used in A. Vertical axis of this plot is at the right, in Hz. Lower panel: 
APamp plotted as a function of time and trace number. (See X-axes in C.) The vertical data scattering represents slight variations in 
APamp for the ~50 APs fired by the current step. “*” identifies the time point when the traces shown in A were selected. (C) IPSP 
amplitude plotted in the same format as B. (D) The first APs in A2 are aligned and expanded for comparison. 	
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Figure.2 LEV’s effects were irreversible.(A) Time line of APamp in response to 200 µM 4-AP (grey arrow), 
LEV and washout. APamp showed continuous decline during a 90 minute washout.  (B) IPSPs recorded 
simultaneously with the APs used in A. The slight increase in IPSP during the early stage of LEV treatment could 
be attributed to an increase in facilitation due to an increase in the number of APs evoked by the 12 nA current 
step. Rin increased during the entire experiment in this preparation.  	
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                   LEV induced reduction in APamp shown in Figures 1 and 2 were obtained 
from the 1° BP. Since the LEV entry point is localized in the presynaptic terminals, we 
next examined whether it was possible to observe the spread of LEV actions from 
terminals to distal, secondary branches and, finally, to the proximal, primary branch. 
TECC was next performed in a configuration where the electrodes were placed as far 
apart as possible, one at the 1° BP while the other in a secondary branch ~1 mm distal to 
the 1° BP (Fig.3A1 and A2 rectangular insets). (The opener preparation, and the axonal 
arborization, used in this study was 2-3 mm in total length (Lin 2013).) This 
configuration allowed us to compare APs conducting both orthodromically and 
antidromically, by injecting current steps through proximal or distal electrodes. Figure 
3A illustrates APs recorded with the distal (A1: APortho) and proximal (A2: APanti) 
electrodes. APortho exhibits a gradual upturn around threshold, similar to that of APs 
initiated “locally” (Yu et al. 2008), and a sloping trajectory between APs (Fig.3A1,B1). 
 
 
            APanti exhibits an abrupt initial upturn (Fig.3A2,B2) and a flat trajectory between 
APs. The characteristics AP trajectory around threshold are better illustrated in phase 
plots (Fig.3C1, C2 and insets), where the APanti exhibits a characteristic “kink” while 
APortho shows a smoother upturn. In addition to the kink, the phase plot of APanti shows 
two components in the rising phase (Fig.3C2 arrows), suggesting a slight delay between 
		 22 
charging current induced depolarization and the remaining rise in AP attributable to local 
inward current. Addition of LEV reduced the amplitude of APanti but not that of APortho  
 
(Fig.3B and D). The reduction in APanti amplitude can be attributed to a reduction in 
inward current at the 1° BP, because the initial depolarization generated by charging 
current, which is originated from AP evoked by the distal electrode located 1 mm away, 
appears unaffected by LEV (Fig.3C2 inset). Only the later part of the AP rising phase 
medicated by local inward current is reduced. The preferential reduction in APanti was 
observed in 4 of the 4 preparations tested, and in no case was the initial rise in dv/dt 
follow the kink altered by LEV. Thus, LEV seems to reduce axonal excitability by 
targeting the inward current of proximal branches, despite the expectation that this drug 
enters axons first in the terminals and should affect the secondary branches before the 
primary branches.   
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Figure.3 LEV preferentially inhibits AP at the1° BP. (A1) AP evoked from the 1° BP and recorded at a distal 2° 
branch. (A2) AP evoked at the 2° branch and recorded at the 1° BP. Only APanti exhibited a reduction in amplitude in 
LEV (A2 grey). Insets in circles: hyperpolarization used to monitor Rin. Insets in rectangles: recording and stimulation 
configurations. (B1 and B2) First APs recorded before and after LEV were aligned and expanded for comparison. (C1 
and C2) Phase plots of AP trains shown in A1 and A2. LEV mainly reduces the dv/dt maximum of APanti. A subtle 
inflexion on the rising phase of APanti phase plot (arrows) suggests a slight delay between charging depolarization and 
local spiking. (D1 and D2) Timeline of APamp plots of APortho and APanti, illustrating selective effect of LEV on APanti.   
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Discussion 
 
            In this report, we utilized a crayfish opener flexor preparation to investigate the 
cellular mechanisms underlying the antiepileptic effects of LEV at the synapse level, our 
results are consistent with previous findings derived from the mammalian CNS synapses, 
namely that LEV enhances synaptic depression during high frequency stimulation. 
Intracellular recordings of motor axons suggest a possible role for LEV in modulating 
axonal excitability, we believe that the modulation of axonal excitability by LEV, 
together with the depressive effect on synaptic transmission, may contribute to the 
antiepileptic effects of this medication. Our findings put forward a novel mechanism of 
LEV in addition to the existing vesicular hypothesis suggested for the drug.  
 
Inhomogeneous Distribution of Channels in the Motor Axons 
 
                 Previous studies of the crayfish NMJ have demonstrated that the spatial 
distribution of voltage gated channels along the proximo-distal axis in the motor axons is 
inhomogeneous. Functionally, this non-uniform channel distribution serves to minimize 
backfiring of action potentials. This variation in channel distribution is not unique to 
crayfish NMJ, terminals of vertebrate NMJ and mammalian CNS are also known to have 
low excitability (Brigant and Mallart 1982; Spirou et al. 2008).  
 
           Previous physiological studies have examined the spatial variation in channel 
distribution with the presence of different pharmacological agents in the crayfish motor 
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axons. For instance, examination of the effects of low concentrations (1 nM) of 
tetrodotoxin (TTX) on the excitability of axon branches showed that the distal branches 
were more sensitive to TTX administration than the proximal branches. Evaluation of 
action potential amplitude, rate of rise, and threshold illustrated that the 2° BP was less 
excitable when TTX was present. These parameters were not as significantly reduced 
with (1 nM) of TTX in the 1° BP.  These findings support the idea that TTX 
preferentially reduced excitability at distal branches due to the difference in channel 
expression in these regions.  When action potential conduction was compared between 
the 1° BP and 2° BP, action potential propagation properties were altered in the presence 
of TTX such that AP traveling towards the terminals would degrade as it was not 
supported by the same Na+ channel density expressed in the proximal regions. It should 
also be noted that the additional of 4-AP with TTX resulted in a more noticeable impact 
of partially blocking Na+ channels with TTX (Lin. 2013). These findings mirror the 
complex nature of action potential conduction properties in an axon and emphasize role 
of channel kinetics and inward and outward current interactions in determining the 
excitability of a neuronal compartment.  
 
           In a different study, it was also demonstrated that 4-AP sensitive voltage activated 
K+ channels are concentrated in the distal branches. Moreover, it was further revealed 
that the 4-AP sensitive K+ channels have a low excitation threshold and fast activation 
kinetics (Lin. 2012;2016).  As a result, distal axons exhibited stronger subthreshold K+ 
channel activity and are hypothesized to be less excitable than the proximal branches.  
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Together these studies provide important contextual information to our own experimental 
findings. Our results are consistent with the rational of inhomogeneous channel 
expression. In our experiments, LEV’s administration altered action potential propagation 
in the antidromic direction in comparison to the orthodromic direction (Fig.3D2). 
Therefore, it is important to interpret our results in the context of the non-uniform 
channel distribution and the presence of 4-AP.  
 
  
The AIS and Action Potential Propagation Properties 
 
       The axon initial segment (AIS) exhibits the lowest excitation threshold for 
action potentials. The low threshold at AIS is attributable to channel types, density and 
the local dimension. As a result, action potentials initiated by somatic current injection 
typically exhibit an initial charging component which is then followed by full action 
potential due to sodium influx at soma.  The initial charging component, visible as a 
“kink” in phase plots, is mediated by AP propagating from AIS toward soma (Yu et al. 
2008). The charging current depolarizes soma rapidly and in turn opens a sufficient 
number of somatic sodium channels to generate a full size AP. Our phase plots exhibited 
a similar “kink” in the antidromic APs before and after LEV. The schematic that LEV 
induced in the second compartment of the rising phase highlighted by the initial charging 
component, suggests that LEV might be modulating voltage-gated channel at the 1° BP. 
The emphasis on channel distribution and kinetics is based on the observation that the 
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initial rise of the phase plots in did not change in the presence of LEV (Fig.3C2). 
Therefore, it appears that AP initiated by distal electrode was normal in LEV as it back-
propagates towards the 1° BP and generates normal “charging depolarization”. However, 
reduced excitability in proximal axon in LEV could not support the same AP amplitude 
as that recorded before LEV. This observation is analogous to a reduction in an 
antidromically invading AP recorded in soma, when somatic Na+ channel was inactivated 
by depolarization (Hu et al. 2009). Therefore, LEV seems to modulate the net inward 
current activated by the initial charging depolarization at the 1° BP.  
 
The consequence of LEV induced decrease in proximal axon excitability could 
have significant functional outcomes. For example, changes in AP amplitude could affect 
AP conduction velocity and may transmitter release. Thus far, the mechanism modulating 
LEV induced reduction in antidromic AP amplitude has not been resolved 
 
LEV Might Modulate Axonal Excitability 
 
      With the analogy outlined above, the observation that LEV selectively affect the local  
AP component measured at the primary branching point suggests that LEV could reduce 
axonal excitability of the proximal axon. This conclusion, though supported by the data, 
is somewhat counter intuitive for two reasons. First, LEV presumably enters axon 
through endocytosis and distal branches should be exposed to a higher LEV 
concentration than proximal branches. Second, distal branches have been shown to 
exhibit lower membrane excitability and yet they are not affected by LEV.  With these 
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two considerations, it is reasonable to suggest that LEV did not target sodium channels in 
the crayfish motor axon. Specifically, if sodium channels were targeted by LEV then the 
excitability of distal branches should be preferentially affected, given the known low 
sodium channel density and expected high LEV concentration there. It remains possible 
that sodium channels in distal and proximal branches are of different molecular identities 
and LEV is effective on a specific molecular target. The remaining possibility will be that 
LEV positively modulate a fast potassium channel which could curtain AP amplitude 
generated locally. Further analysis of LEV effects in the presence of specific potassium 
channel blockers is needed to resolve these possibilities.  
 
 
 
Protein Homeostasis and Modulating Presynaptic Protein Expression 
 
The difference in the timing of reduction in APamp and IPSP was a curious 
observation. Previous studies have suggested that LEV directly altered transmitter 
secretion processes and enhanced synaptic depression (Lynch et al. 2004; Meehan et al. 
2011). Following this logic, the asynchrony would suggest that LEV modulates release 
processes and voltage gated channels by two processes with distinct kinetics. However, 
we cannot rule out the possibility that the reduction in IPSP was mainly due to decreased 
APamp which needs to reach a threshold level in the presynaptic terminal before 
transmitter release is affected. Based on previous literature, LEV’s binds to the vesicular 
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protein SV2A and consequently alters presynaptic release. Therefore, it was also 
proposed that LEV exerts its antiepileptic action mainly on active terminals (Marcotulli et 
al. 2017).  Our experimental set up allows us to capture the temporal order of events 
following LEV’s administration to the axon terminals. However, it is difficult to 
speculate further unless we know the stability of APamp in terminal varicosities under 
LEV.   
 
Our results are consistent with previous research suggesting that LEV enhances 
synaptic depression through a presynaptic mechanism. However, the temporal lag 
between the reduction in APamp and IPSP needs further examination. A recent study 
highlighted LEV’s effect on presynaptic protein expression. It was shown that LEV did 
not alter any of the glutamatergic protein transporters (GLUT1, GLUT2, VGAT) and did 
not affect SV2A levels, the LEV binding receptor. However, the study uncovered that 
LEV binding to SV2A results in an upregulation of the protein LRRK2, a proteostasis 
regulator. LRRK2 governs the homeostasis of synaptic proteins by mediating autophagic 
protein degradation processes, promoting translation and accelerating endocytosis 
(Martin et al. 2014; Maas et al. 2018). Additionally, LRRK2 has an important role in 
several functional pathways, including chaperone pathway and cellular stress, proteins 
associated with the cytoskeleton and trafficking, and phosphorylation and kinase activity 
(Dachsel et al. 2007). The long-term effects of the interaction between LEV and SV2A 
was suggested to be the  down-regulation of vesicular proteins which in term reduces the 
strength of hyper-active terminals and prevents epileptogenic activity (Meehan et al., 
		 30 
2011; Marcotulli et al. 2017). Therefore, we speculate that LEV might also be involved in 
controlling synaptic strength and plasticity.  
 
The time scale of the LRRK2 upregulation was studied 14 days after chronic LEV 
treatment. Data presented in this report were obtained from experiments that lasted ~ 4 
hours. Although comparing two studies with a notable difference in time frame is not 
convincing. It is also plausible that LEV induced changes in excitability could in turn 
promote the alterations in protein expression during the chronic administration of the 
drug. It remains possible that the results reported here are due to a chain of biological 
changes modulated by LRRK2. For example, changes in axonal excitability and synaptic 
transmission would have in part be modulated by LRRK2 induced biochemical changes. 
It is also equally possible that changes in axonal excitability play a role in triggering the 
biochemical events related to LRRK2. Whether LRRK2 upregulation is related to the 
suppression of synaptic release at the crayfish neuromuscular junction synapses remains 
to be resolved. The possible role of LRRK2 on axonal excitability and synaptic 
transmission would be tractable with the appropriate biochemical tools that are applicable 
to the opener preparation.  
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CONCLUSION 
 
        Functional Significance: LEV is known to successfully treat patients who failed to 
respond to AEDs that target ion channels. Actions of this drug on release process has 
been characterized at both physiological and molecular levels. Whether this medication 
directly influences neuronal excitability is less well documented. Although there are 
indications that LEV inhibits Ca and Na channels (Hanaya et al. 2011; Vogl et al. 2012), 
direct effect of LEV on axonal firing has not been reported. This study provide examples 
for how neuronal excitability may be affected by LEV, and, raises the possibility that part 
of the clinical efficacy of LEV is, in addition to synaptic release, is due to modulation of 
voltage gated channels in the axon or even soma.  
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